JP2018515493A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515493A5
JP2018515493A5 JP2017557901A JP2017557901A JP2018515493A5 JP 2018515493 A5 JP2018515493 A5 JP 2018515493A5 JP 2017557901 A JP2017557901 A JP 2017557901A JP 2017557901 A JP2017557901 A JP 2017557901A JP 2018515493 A5 JP2018515493 A5 JP 2018515493A5
Authority
JP
Japan
Prior art keywords
composition
amino acid
acid sequence
infusion
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017557901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/060360 external-priority patent/WO2016177913A1/en
Publication of JP2018515493A publication Critical patent/JP2018515493A/ja
Publication of JP2018515493A5 publication Critical patent/JP2018515493A5/ja
Priority to JP2021036849A priority Critical patent/JP2021100943A/ja
Priority to JP2023078474A priority patent/JP7685008B2/ja
Priority to JP2025082282A priority patent/JP2025118898A/ja
Pending legal-status Critical Current

Links

JP2017557901A 2015-05-07 2016-05-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 Pending JP2018515493A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021036849A JP2021100943A (ja) 2015-05-07 2021-03-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2023078474A JP7685008B2 (ja) 2015-05-07 2023-05-11 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2025082282A JP2025118898A (ja) 2015-05-07 2025-05-16 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562158153P 2015-05-07 2015-05-07
US62/158,153 2015-05-07
US201562221393P 2015-09-21 2015-09-21
US62/221,393 2015-09-21
US201562246949P 2015-10-27 2015-10-27
US62/246,949 2015-10-27
PCT/EP2016/060360 WO2016177913A1 (en) 2015-05-07 2016-05-09 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021036849A Division JP2021100943A (ja) 2015-05-07 2021-03-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2018515493A JP2018515493A (ja) 2018-06-14
JP2018515493A5 true JP2018515493A5 (enExample) 2019-06-13

Family

ID=56008603

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017557901A Pending JP2018515493A (ja) 2015-05-07 2016-05-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2021036849A Pending JP2021100943A (ja) 2015-05-07 2021-03-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2023078474A Active JP7685008B2 (ja) 2015-05-07 2023-05-11 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2025082282A Pending JP2025118898A (ja) 2015-05-07 2025-05-16 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021036849A Pending JP2021100943A (ja) 2015-05-07 2021-03-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2023078474A Active JP7685008B2 (ja) 2015-05-07 2023-05-11 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2025082282A Pending JP2025118898A (ja) 2015-05-07 2025-05-16 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Country Status (13)

Country Link
US (2) US11034760B2 (enExample)
EP (1) EP3292147A1 (enExample)
JP (4) JP2018515493A (enExample)
KR (1) KR20180004254A (enExample)
CN (2) CN121588213A (enExample)
AU (1) AU2016257023B2 (enExample)
BR (1) BR112017023867A2 (enExample)
CA (1) CA2985001A1 (enExample)
EA (1) EA037532B1 (enExample)
IL (3) IL282923B2 (enExample)
MX (3) MX2017014294A (enExample)
SG (1) SG10202108996PA (enExample)
WO (1) WO2016177913A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
BR112017023867A2 (pt) 2015-05-07 2018-07-24 Novimmune Sa métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
AU2017352033A1 (en) * 2016-10-24 2019-06-06 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CN109164266B (zh) * 2017-11-27 2021-09-24 首都医科大学附属北京友谊医院 细胞因子在区分淋巴瘤相关噬血细胞综合征和淋巴瘤中的应用
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
WO2019173676A1 (en) * 2018-03-09 2019-09-12 Children's Hospital Medical Center Compositions and methods for the treatment of macrophage activation syndrome
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
JP7396213B2 (ja) * 2020-06-22 2023-12-12 Tdk株式会社 データ解析システム、データ解析方法及びデータ解析プログラム
CN115812671B (zh) * 2022-11-17 2024-07-19 青岛大学 帕金森病动物模型的建立方法及其应用
WO2024254401A1 (en) 2023-06-09 2024-12-12 Children's Hospital Medical Center Treatment of stem cell graft failure
CN118266439A (zh) * 2024-04-26 2024-07-02 倍科为(天津)生物技术有限公司 一种斑马鱼继发性噬血细胞综合征模型的构建方法及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599306A (en) 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69322289T2 (de) 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
US20030059428A1 (en) 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
CA2352572C (en) 1998-12-01 2010-04-20 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6861056B2 (en) 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
CA2486147A1 (en) 2002-05-17 2003-11-27 Protein Design Labs, Inc. Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
US20040052791A1 (en) 2002-05-22 2004-03-18 Rolf Ehrhardt Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
GB0314461D0 (en) 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EA013118B1 (ru) 2005-01-27 2010-02-26 Новиммун С.А. Антитела против интерферона-гамма и способы их применения
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
GB0607943D0 (en) 2006-04-21 2006-05-31 Novartis Ag Biomarkers for chronic transplant dysfunction
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
DK2234600T3 (da) 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
US20110256149A1 (en) 2008-10-09 2011-10-20 Medimmune, Llc Antibody formulation
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
CA2830806C (en) * 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
BR112014012607A2 (pt) 2011-11-23 2017-06-20 Amgen Inc métodos de tratamento usando um inibidor de interferon gama
EP3156071A4 (en) 2014-06-10 2018-01-10 Meiji Seika Pharma Co., Ltd. Stable aqueous adalimumab preparation
EP3237000A1 (en) * 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
BR112017023867A2 (pt) 2015-05-07 2018-07-24 Novimmune Sa métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
AU2017352033A1 (en) 2016-10-24 2019-06-06 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Similar Documents

Publication Publication Date Title
JP2018515493A5 (enExample)
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
EP2750709B1 (en) Cachexia treatment
KR102104296B1 (ko) 종양성 질병들에 대한 치료
JP2014114288A5 (enExample)
JP7288927B2 (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用
JP7145162B2 (ja) 化膿性汗腺炎の処置
CN104800844A (zh) 使用il-17拮抗剂治疗类风湿性关节炎的方法
AU2014314053B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
KR20230155586A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
AU2016250388A1 (en) Treatment for rheumatoid arthritis
KR20200088857A (ko) Il-17 길항제에 의한 화농성 한선염의 치료
ES2992409T3 (es) Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
RU2014117510A (ru) Лечение ревматоидного артрита
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗ＩＬ－α抗体
JP2019532970A5 (enExample)
KR20230004638A (ko) 화농성 한선염의 치료
WO2019057982A1 (en) TREATMENT OF ATOPIC DERMATITIS
JP2022530063A (ja) 抗体製剤
TW202120546A (zh) 使用介白素-17（il-17）拮抗劑治療狼瘡性腎炎之方法
CN115515978A (zh) 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体
KR20250029297A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
Thomas et al. Individual drugs in rheumatology and the risk of infection
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
CA3187136A1 (en) Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists